Get quick answers to your questions about the article from our AI researcher chatbot
{'id': 'https://openalex.org/W2621360628', 'doi': 'https://doi.org/10.1097/01.npr.0000524665.16846.63', 'title': 'Bolstering your armamentarium with SGLT2 inhibitors', 'display_name': 'Bolstering your armamentarium with SGLT2 inhibitors', 'publication_year': 2017, 'publication_date': '2017-10-18', 'ids': {'openalex': 'https://openalex.org/W2621360628', 'doi': 'https://doi.org/10.1097/01.npr.0000524665.16846.63', 'mag': '2621360628', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/28926495'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1097/01.npr.0000524665.16846.63', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4210206853', 'display_name': 'The Nurse Practitioner', 'issn_l': '0361-1817', 'issn': ['0361-1817', '1538-8662'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310315671', 'host_organization_name': 'Lippincott Williams & Wilkins', 'host_organization_lineage': ['https://openalex.org/P4310315671', 'https://openalex.org/P4310318547'], 'host_organization_lineage_names': ['Lippincott Williams & Wilkins', 'Wolters Kluwer'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'review', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5048644363', 'display_name': 'Lucia M. Novak', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210136823', 'display_name': 'AstraZeneca (Poland)', 'ror': 'https://ror.org/04gdybn86', 'country_code': 'PL', 'type': 'company', 'lineage': ['https://openalex.org/I105036370', 'https://openalex.org/I4210136823']}, {'id': 'https://openalex.org/I137982388', 'display_name': 'Janssen (Belgium)', 'ror': 'https://ror.org/04yzcpd71', 'country_code': 'BE', 'type': 'company', 'lineage': ['https://openalex.org/I1330063522', 'https://openalex.org/I137982388']}, {'id': 'https://openalex.org/I4210100118', 'display_name': 'Novo Nordisk (Finland)', 'ror': 'https://ror.org/0144enb05', 'country_code': 'FI', 'type': 'company', 'lineage': ['https://openalex.org/I189090001', 'https://openalex.org/I2801134892', 'https://openalex.org/I4210100118', 'https://openalex.org/I4210159963']}], 'countries': ['BE', 'FI', 'PL'], 'is_corresponding': False, 'raw_author_name': 'Lucia M. Novak', 'raw_affiliation_strings': ["Lucia Novak has served on the Speaker's Bureau for Novo Nordisk Inc., Janssen Pharmaceuticals Inc., and AstraZeneca Pharmaceuticals LP."], 'affiliations': [{'raw_affiliation_string': "Lucia Novak has served on the Speaker's Bureau for Novo Nordisk Inc., Janssen Pharmaceuticals Inc., and AstraZeneca Pharmaceuticals LP.", 'institution_ids': ['https://openalex.org/I4210136823', 'https://openalex.org/I137982388', 'https://openalex.org/I4210100118']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5066005399', 'display_name': 'Davida F. Kruger', 'orcid': 'https://orcid.org/0000-0002-3188-8132'}, 'institutions': [{'id': 'https://openalex.org/I4210126084', 'display_name': 'Novo Nordisk (United Kingdom)', 'ror': 'https://ror.org/0415cr103', 'country_code': 'GB', 'type': 'company', 'lineage': ['https://openalex.org/I189090001', 'https://openalex.org/I2801134892', 'https://openalex.org/I4210126084', 'https://openalex.org/I4210159963']}, {'id': 'https://openalex.org/I4210153213', 'display_name': 'Boehringer Ingelheim (Australia)', 'ror': 'https://ror.org/05ww0qy02', 'country_code': 'AU', 'type': 'company', 'lineage': ['https://openalex.org/I1330995197', 'https://openalex.org/I4210153213']}, {'id': 'https://openalex.org/I137982388', 'display_name': 'Janssen (Belgium)', 'ror': 'https://ror.org/04yzcpd71', 'country_code': 'BE', 'type': 'company', 'lineage': ['https://openalex.org/I1330063522', 'https://openalex.org/I137982388']}, {'id': 'https://openalex.org/I3019813218', 'display_name': 'Abbott (United Kingdom)', 'ror': 'https://ror.org/03wnay029', 'country_code': 'GB', 'type': 'company', 'lineage': ['https://openalex.org/I3019813218', 'https://openalex.org/I4210088555']}, {'id': 'https://openalex.org/I157075465', 'display_name': 'Bristol-Myers Squibb (Germany)', 'ror': 'https://ror.org/032hfv632', 'country_code': 'DE', 'type': 'company', 'lineage': ['https://openalex.org/I157075465', 'https://openalex.org/I4210091812']}, {'id': 'https://openalex.org/I168537998', 'display_name': 'Eli Lilly (United States)', 'ror': 'https://ror.org/01qat3289', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I168537998']}, {'id': 'https://openalex.org/I4210160666', 'display_name': 'Johnson & Johnson (Brazil)', 'ror': 'https://ror.org/04f89zf73', 'country_code': 'BR', 'type': 'company', 'lineage': ['https://openalex.org/I1330063522', 'https://openalex.org/I4210160666']}, {'id': 'https://openalex.org/I4210149061', 'display_name': 'Novo Nordisk (Germany)', 'ror': 'https://ror.org/03nyzw632', 'country_code': 'DE', 'type': 'company', 'lineage': ['https://openalex.org/I189090001', 'https://openalex.org/I2801134892', 'https://openalex.org/I4210149061', 'https://openalex.org/I4210159963']}, {'id': 'https://openalex.org/I3018075036', 'display_name': 'Sanofi (France)', 'ror': 'https://ror.org/02n6c9837', 'country_code': 'FR', 'type': 'company', 'lineage': ['https://openalex.org/I3018075036']}, {'id': 'https://openalex.org/I4210107308', 'display_name': 'Novo Nordisk (Switzerland)', 'ror': 'https://ror.org/01p1t0k52', 'country_code': 'CH', 'type': 'company', 'lineage': ['https://openalex.org/I189090001', 'https://openalex.org/I2801134892', 'https://openalex.org/I4210107308', 'https://openalex.org/I4210159963']}], 'countries': ['AU', 'BE', 'BR', 'CH', 'DE', 'FR', 'GB', 'US'], 'is_corresponding': False, 'raw_author_name': 'Davida F. Kruger', 'raw_affiliation_strings': ['Davida Kruger has been an advisor for Janssen Pharmaceuticals Inc., Abbott, Boehringer Ingelheim Inc., Dexcom, Eli Lilly, Novo Nordisk, and Sanofi Aventis', 'has received research support from Abbott, Bristol-Myers Squibb, Calibra/Johnson and Johnson, Dexcom, Eli Lilly, IDC, Helmsley Charitable Trust, Lexicon, NIH, Novo Nordisk, and TEVA.', 'has served on the speakers bureau for Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen Pharmaceuticals Inc., Novo Nordisk, and Valeritas'], 'affiliations': [{'raw_affiliation_string': 'Davida Kruger has been an advisor for Janssen Pharmaceuticals Inc., Abbott, Boehringer Ingelheim Inc., Dexcom, Eli Lilly, Novo Nordisk, and Sanofi Aventis', 'institution_ids': ['https://openalex.org/I4210126084', 'https://openalex.org/I4210153213', 'https://openalex.org/I137982388', 'https://openalex.org/I3019813218', 'https://openalex.org/I3018075036']}, {'raw_affiliation_string': 'has received research support from Abbott, Bristol-Myers Squibb, Calibra/Johnson and Johnson, Dexcom, Eli Lilly, IDC, Helmsley Charitable Trust, Lexicon, NIH, Novo Nordisk, and TEVA.', 'institution_ids': ['https://openalex.org/I157075465', 'https://openalex.org/I168537998', 'https://openalex.org/I4210160666', 'https://openalex.org/I4210149061']}, {'raw_affiliation_string': 'has served on the speakers bureau for Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen Pharmaceuticals Inc., Novo Nordisk, and Valeritas', 'institution_ids': ['https://openalex.org/I157075465', 'https://openalex.org/I168537998', 'https://openalex.org/I4210153213', 'https://openalex.org/I4210107308']}]}], 'countries_distinct_count': 10, 'institutions_distinct_count': 12, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.052, 'has_fulltext': True, 'fulltext_origin': 'ngrams', 'cited_by_count': 2, 'citation_normalized_percentile': {'value': 0.172722, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 72, 'max': 76}, 'biblio': {'volume': '42', 'issue': '10', 'first_page': '28', 'last_page': '34'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10401', 'display_name': 'Management of Diabetes Mellitus and Cardiovascular Risk', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2712', 'display_name': 'Endocrinology, Diabetes and Metabolism'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10401', 'display_name': 'Management of Diabetes Mellitus and Cardiovascular Risk', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2712', 'display_name': 'Endocrinology, Diabetes and Metabolism'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T12539', 'display_name': 'Pharmacological Management of Obesity', 'score': 0.9849, 'subfield': {'id': 'https://openalex.org/subfields/2736', 'display_name': 'Pharmacology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10365', 'display_name': 'Functional Bowel Disorders and Gastrointestinal Health', 'score': 0.9522, 'subfield': {'id': 'https://openalex.org/subfields/2715', 'display_name': 'Gastroenterology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/sglt2-inhibitors', 'display_name': 'SGLT2 Inhibitors', 'score': 0.52124}], 'concepts': [{'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.4230916}, {'id': 'https://openalex.org/C177713679', 'wikidata': 'https://www.wikidata.org/wiki/Q679690', 'display_name': 'Intensive care medicine', 'level': 1, 'score': 0.3596505}], 'mesh': [{'descriptor_ui': 'D003924', 'descriptor_name': 'Diabetes Mellitus, Type 2', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D003924', 'descriptor_name': 'Diabetes Mellitus, Type 2', 'qualifier_ui': 'Q000451', 'qualifier_name': 'nursing', 'is_major_topic': True}, {'descriptor_ui': 'D000077203', 'descriptor_name': 'Sodium-Glucose Transporter 2 Inhibitors', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D001559', 'descriptor_name': 'Benzhydryl Compounds', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D001559', 'descriptor_name': 'Benzhydryl Compounds', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000068896', 'descriptor_name': 'Canagliflozin', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D000068896', 'descriptor_name': 'Canagliflozin', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D003924', 'descriptor_name': 'Diabetes Mellitus, Type 2', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D005960', 'descriptor_name': 'Glucosides', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D005960', 'descriptor_name': 'Glucosides', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D016032', 'descriptor_name': 'Randomized Controlled Trials as Topic', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000077203', 'descriptor_name': 'Sodium-Glucose Transporter 2 Inhibitors', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1097/01.npr.0000524665.16846.63', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4210206853', 'display_name': 'The Nurse Practitioner', 'issn_l': '0361-1817', 'issn': ['0361-1817', '1538-8662'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310315671', 'host_organization_name': 'Lippincott Williams & Wilkins', 'host_organization_lineage': ['https://openalex.org/P4310315671', 'https://openalex.org/P4310318547'], 'host_organization_lineage_names': ['Lippincott Williams & Wilkins', 'Wolters Kluwer'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/28926495', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 42, 'referenced_works': ['https://openalex.org/W1517491980', 'https://openalex.org/W1575345815', 'https://openalex.org/W1834962231', 'https://openalex.org/W1987553321', 'https://openalex.org/W1990025047', 'https://openalex.org/W1991334358', 'https://openalex.org/W1995006519', 'https://openalex.org/W1995324236', 'https://openalex.org/W2002810160', 'https://openalex.org/W2008687581', 'https://openalex.org/W2010055261', 'https://openalex.org/W2024372370', 'https://openalex.org/W2026412750', 'https://openalex.org/W2030192134', 'https://openalex.org/W2052503411', 'https://openalex.org/W2072040765', 'https://openalex.org/W2077038286', 'https://openalex.org/W2077636750', 'https://openalex.org/W2082818798', 'https://openalex.org/W2097620901', 'https://openalex.org/W2099484221', 'https://openalex.org/W2100796772', 'https://openalex.org/W2118613762', 'https://openalex.org/W2130570549', 'https://openalex.org/W2142593697', 'https://openalex.org/W2146264128', 'https://openalex.org/W2152413054', 'https://openalex.org/W2160088494', 'https://openalex.org/W2162693177', 'https://openalex.org/W2167836895', 'https://openalex.org/W2173169652', 'https://openalex.org/W2175616918', 'https://openalex.org/W2179831365', 'https://openalex.org/W2273304042', 'https://openalex.org/W2290760722', 'https://openalex.org/W2340312426', 'https://openalex.org/W2341643234', 'https://openalex.org/W2567274778', 'https://openalex.org/W2653321410', 'https://openalex.org/W2782023847', 'https://openalex.org/W2917198334', 'https://openalex.org/W4256316440'], 'related_works': ['https://openalex.org/W4389568370', 'https://openalex.org/W3108674512', 'https://openalex.org/W3032375762', 'https://openalex.org/W3031052312', 'https://openalex.org/W2748952813', 'https://openalex.org/W2148612803', 'https://openalex.org/W2080531066', 'https://openalex.org/W1995515455', 'https://openalex.org/W1506200166', 'https://openalex.org/W1489783725'], 'abstract_inverted_index': {'Sodium-glucose': [0], 'cotransporter-2': [1], 'inhibitors': [2], 'have': [3], 'a': [4, 30], 'unique': [5], 'mechanism': [6], 'of': [7, 33, 44], 'action': [8], 'in': [9], 'the': [10, 38], 'kidneys': [11], 'that': [12], 'causes': [13], 'glucosuria,': [14], 'which': [15], 'lowers': [16], 'plasma': [17], 'glucose.': [18], 'They': [19], 'are': [20], 'also': [21], 'associated': [22], 'with': [23], 'reduced': [24], 'body': [25], 'weight': [26], 'and': [27, 29, 41, 47], 'BP,': [28], 'low': [31], 'incidence': [32], 'hypoglycemia.': [34], 'This': [35], 'article': [36], 'reviews': [37], 'pharmacologic': [39], 'profiles': [40], 'clinical': [42], 'implications': [43], 'canagliflozin,': [45], 'dapagliflozin,': [46], 'empagliflozin.': [48]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2621360628', 'counts_by_year': [{'year': 2023, 'cited_by_count': 1}, {'year': 2020, 'cited_by_count': 1}], 'updated_date': '2024-08-21T19:32:01.271530', 'created_date': '2017-06-09'}